Want to see APNHY full AI Analyst Report?
APNHY Stock Chart & Stats
$6.80
$0.00(0.00%)
At close: 4:00 PM EST
$6.80
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$5.24 - $9.68
Previous CloseN/A
Volume14.00
Average Volume (3M)710.00
Market Cap
$4.32B
Enterprise Value$92.48B
Total Cash (Recent Filing)$5.61B
Total Debt (Recent Filing)$32.91B
Price to Earnings (P/E)―
Beta0.31
Next Earnings
Sep 02, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield2.15%
Share Statistics
EPS (TTM)-4.67
Shares Outstanding446,252,320
10 Day Avg. Volume0
30 Day Avg. Volume710
Financial Highlights & Ratios
PEG Ratio0.39
Price to Book (P/B)0.63
Price to Sales (P/S)1.23
P/FCF Ratio512.59
Enterprise Value/Market Cap21.42
Enterprise Value/Revenue2.45
Enterprise Value/Gross Profit5.86
Enterprise Value/Ebitda57.36
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.76
Revenue Forecast (FY)$2.29B
Bulls Say, Bears Say
Bulls Say
Improving Cash GenerationSustained operational cash generation and disciplined CapEx materially improve liquidity and self‑funding capacity. Over 2–6 months this strengthens ability to service debt, finance working capital and support restructuring/organic growth without relying solely on asset sales, reducing refinancing risk.
Commercial Pharma Revenue And Margin StrengthA growing, high‑margin Commercial Pharma franchise provides durable cash flow and earnings resilience versus manufacturing volatility. Stable branded/generic positions and double‑digit EBITDA growth in the segment underpin core profitability and funding for reinvestment and margin expansion over the medium term.
APAC Divestment To Materially Reduce DebtA completed sizeable disposals program that materially extinguishes net debt would transform the balance sheet, cut interest costs and free capacity for strategic investments. This structural deleveraging can improve credit metrics and lengthen the time horizon for operational recovery if execution delivers expected proceeds.
Bears Say
Manufacturing And Sterile Business CollapseA severe and persistent manufacturing/sterile downturn erodes diversification, reduces group gross margins and creates dependency on Commercial Pharma. Recovery requires contract wins and sterile restructuring; failure to rebuild volumes would leave lasting margin dilution and capacity underutilization.
Historically Weak Cash ConversionPoor historical cash conversion undermines funding flexibility and raises reliance on asset sales or external financing for capex and debt service. Even with recent half‑year improvement, legacy weak conversion signals structural working capital and profit‑quality issues that must be resolved to sustain operations without disruptive financing.
Elevated Leverage And Weak ReturnsHigh net leverage combined with negative shareholder returns constrains strategic optionality and increases vulnerability to macro or currency shocks. Even after planned asset sales, historically weak ROIC/ROE indicates past capital misallocation, and restoring returns will take sustained operational improvement beyond immediate liquidity fixes.
Aspen Pharmacare News
APNHY FAQ
What was Aspen Pharmacare’s price range in the past 12 months?
Aspen Pharmacare lowest stock price was $5.24 and its highest was $9.68 in the past 12 months.
What is Aspen Pharmacare’s market cap?
Aspen Pharmacare’s market cap is $4.32B.
When is Aspen Pharmacare’s upcoming earnings report date?
Aspen Pharmacare’s upcoming earnings report date is Sep 02, 2026 which is in 59 days.
How were Aspen Pharmacare’s earnings last quarter?
Aspen Pharmacare released its earnings results on Mar 03, 2026. The company reported $0.19 earnings per share for the quarter, beating the consensus estimate of N/A by $0.19.
Is Aspen Pharmacare overvalued?
According to Wall Street analysts Aspen Pharmacare’s price is currently Overvalued.
Does Aspen Pharmacare pay dividends?
Aspen Pharmacare pays a Annually dividend of $0.122 which represents an annual dividend yield of 2.15%. See more information on Aspen Pharmacare dividends here
What is Aspen Pharmacare’s EPS estimate?
Aspen Pharmacare’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Aspen Pharmacare have?
Aspen Pharmacare has 446,252,320 shares outstanding.
What happened to Aspen Pharmacare’s price movement after its last earnings report?
Aspen Pharmacare reported an EPS of $0.19 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -2.191%.
Which hedge fund is a major shareholder of Aspen Pharmacare?
Currently, no hedge funds are holding shares in APNHY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Aspen Pharmacare Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-45.29%
12-Months-Change
Fundamentals
Return on Equity
-2.41%
Trailing 12-Months
Asset Growth
6.75%
Trailing 12-Months
Company Description
Aspen Pharmacare
Aspen Pharmacare Holdings Limited, together with its subsidiaries, manufactures and markets specialty and branded pharmaceutical products in Africa, the Middle East, the Americas, Europe CIS, Australasia, and Asia. It operates through Commercial Pharmaceuticals and Manufacturing segments. The company offers injectables for therapeutic areas, such as anaesthetics, anticoagulants, antithrombotic agents, analgesics, and hormone replacement medicines under the Arixtra, Diprivan, Fraxiparine, Marcaine, Sustanon, and Xylocaine brands; over-the-counter medicines under the Emla, Maltofer, Ovestin, Solpadeine, and Xylocaine brands; and prescription products for anti-inflammatories, immunosuppressants, hypothyroidism, anti-gout, analgesics, and corticosteroids under the Eltroxin, Imuran, Lipitor, Lyrica, and Zyloric brands. It also manufactures active pharmaceutical ingredients, finished dose forms, and heparins, as well as steriles, oral solid doses, liquids, semi-solids, and biologicals. The company exports its products. Aspen Pharmacare Holdings Limited was founded in 1850 and is headquartered in Durban, South Africa.
APNHY Company Deck
APNHY Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call conveys a balanced picture: strong operational cash generation, clear commercial pharma momentum (notably GLP‑1 traction), and a material APAC divestment that should materially strengthen the balance sheet and unlock shareholder value. Offsetting these positives are significant near‑term manufacturing and sterile segment setbacks (large EBITDA and revenue hits from lost contracts), a meaningful short‑term decline in group earnings, and ongoing macro/regulatory and currency risk. Management presented a defined recovery plan (cost reshaping, contract commercialization, insulin ramp, French site wins and sterile restructuring) and targets FY27 restoration of prior EBITDA levels, but execution is required to convert the improvements signaled into sustainable results.View all APNHY earnings summariesTechnical Analysis
Perrigo Company
―
Supernus Pharmaceuticals
―
HUTCHMED
―
Amneal Pharmaceuticals
―
Alvotech
―
Ownership Overview
―
Insiders
<0.01% Mutual Funds
<0.01% Other Institutional Investors
100.00% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---